

VYGORIS announces distribution agreement with Dr Pflieger GmbH, Germany, to distribute and promote Mitem® in Germany.

London, UK, June 19, 2018 – Vygoris Limited is pleased to announce an exclusive German distribution agreement with Dr Pflieger GmbH, Bamberg, Germany, for the supply and distribution of Mitem® to the German pharmaceutical market.

Under the terms of the exclusive agreement, Vygoris will supply the finished product and Dr Pflieger will promote and distribute. Mitem® is a cancer-fighting medication used primarily to treat bladder cancer as well as some types of colon and stomach cancer.

A proven standard of care

Approved in the early 1960's and used in more than 80 countries worldwide, Mitem belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics called actinomycins. It kills cancer cells by interfering with their growth and reproduction and can be used alone or in combination with other antineoplastic medications, radiation, or surgery.

About Vygoris

Located in the UK, Vygoris Limited is a newly formed subsidiary of the French specialist generics company Substipharm. Its focus is on specialized pharmaceutical products.

“This deal is a key part of our growth strategy as we are looking for strong partners in every country where we supply the product. Dr Pflieger's both reputation and dominance in the German urology market make them a perfect fit for our long-term objectives in this country” – Philippe Beaupere, Managing Director, Vygoris UK

About Dr Pflieger

Dr Pflieger is a German mid-size pharmaceutical company focused on urology, dermatology and self-medication. The company is owned by the charitable Doktor Robert Pflieger Foundation.

“Mitem® fits perfectly to our current product portfolio in urology. This exclusive agreement with Vygoris is a next step in following our corporate strategy to strengthen and expand our existing indication areas with the help of both established and innovative products” – Günter Auerbach and Ralf Will, Managing Directors, Dr. Pflieger GmbH.